These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 27903272)

  • 21. GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells.
    Kosta A; Mekhloufi A; Lucantonio L; Zingoni A; Soriani A; Cippitelli M; Gismondi A; Fazio F; Petrucci MT; Santoni A; Stabile H; Fionda C
    Front Immunol; 2022; 13():942640. PubMed ID: 35967396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma.
    Fionda C; Soriani A; Zingoni A; Santoni A; Cippitelli M
    Biomed Res Int; 2015; 2015():178698. PubMed ID: 26161387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and role of MHC class I-related chain in myeloma cells.
    Okamoto M; Inaba T; Yamada N; Uchida R; Fuchida SI; Okano A; Shimazaki C; Taniwaki M
    Cytotherapy; 2006; 8(5):509-16. PubMed ID: 17050256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
    Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
    J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
    Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
    J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.
    Sarkar S; Germeraad WT; Rouschop KM; Steeghs EM; van Gelder M; Bos GM; Wieten L
    PLoS One; 2013; 8(5):e64835. PubMed ID: 23724099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.
    Bedel R; Thiery-Vuillemin A; Grandclement C; Balland J; Remy-Martin JP; Kantelip B; Pallandre JR; Pivot X; Ferrand C; Tiberghien P; Borg C
    Cancer Res; 2011 Mar; 71(5):1615-26. PubMed ID: 21257710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
    Shiraishi K; Mimura K; Kua LF; Koh V; Siang LK; Nakajima S; Fujii H; Shabbir A; Yong WP; So J; Takenoshita S; Kono K
    J Gastroenterol; 2016 Dec; 51(12):1101-1111. PubMed ID: 27002316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
    Wu X; Tao Y; Hou J; Meng X; Shi J
    Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
    Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
    Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MICA/IL-12: A novel bifunctional protein for killer cell activation.
    Tietje A; Yang X; Yu X; Wei Y
    Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner.
    Yamada N; Yamanegi K; Ohyama H; Hata M; Nakasho K; Futani H; Okamura H; Terada N
    Int J Oncol; 2012 Dec; 41(6):2005-12. PubMed ID: 22992985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.
    Nwangwu CA; Weiher H; Schmidt-Wolf IGH
    Hematol Oncol; 2017 Dec; 35(4):719-725. PubMed ID: 27430430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
    Vulpis E; Loconte L; Cassone C; Antonangeli F; Caracciolo G; Masuelli L; Fazio F; Petrucci MT; Fionda C; Soriani A; Cerboni C; Cippitelli M; Santoni A; Zingoni A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDO1 impairs NK cell cytotoxicity by decreasing NKG2D/NKG2DLs via promoting miR-18a.
    Zhang J; Han X; Hu X; Jin F; Gao Z; Yin L; Qin J; Yin F; Li C; Wang Y
    Mol Immunol; 2018 Nov; 103():144-155. PubMed ID: 30268986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.